Identifies themes and clusters of stock movements
Market TodayThemes and Stocks SummaryThematic Stock SearchClick here for daily refresh schedule
BFRA - Biofrontera AG
$7.99
-0.18(-2.20%)3:03:30 PM 1/22/2021
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.
Stock Chart
No summary

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from 

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Related Topics
leak data

Related Topics

Stock news

    01/8/2021BFRA
    Biofrontera announces preliminary revenue figures for the full year 2020

    Leverkusen, Germany, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today reported preliminary, unaudited revenue for the full year 2020. Biofrontera Group's preliminary unaudited revenue for the period January 1 to December 31, 2020 was in the range of EUR 30.3 million to EUR 30.6 million compared to EUR 31.3 million in 2019.Preliminary revenues from product sales in the US were around ...

    01/7/2021BFRA
    Cologne Higher Regional Court grants approval of capital increase

    Leverkusen, Germany, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, announces that the Cologne Higher Regional Court has granted the release of the capital increase resolved by the Annual General Meeting on May 28, 2020. On May 28, 2020, the Annual General Meeting had resolved, with the required majority, to increase the Company's share capital by issuing up to 8,969,870 new registered n...

    12/7/2020BFRA
    Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia

    Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö, Sweden, today signed an exclusive license and supply agreement for the marketing of both Ameluz® and BF-RhodoLED® in Sweden, Norway, Denmark, Finland and Iceland. According to the agreement, Galenica AB of Malmö, Sweden, receives exclusive distribution rights for the Nordic regions, whereby Biofrontera ...

    11/12/2020BFRA
    Biofrontera AG to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Biofrontera AG (NASDAQ:BFRA) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 12, 2020 at 2:00 PM Eastern Time.

    11/12/2020BFRA
    Biofrontera AG resolves mandatory conversion of subordinated mandatory convertible bonds

    Leverkusen, Germany, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, has issued a 1.00% qualified subordinated mandatory convertible bond 2020/2021 (ISIN: DE000A3E4548 / WKN: A3E454) in August 2020. Within the scope of the issuance, 2,638,150 qualified subordinated mandatory convertible bearer bonds ("Bonds") with a nominal value of EUR 3.00 each were issued. The term of the Bonds began on...

    11/11/2020BFRA
    Biofrontera: Q3 Earnings Insights

    Shares of Biofrontera (NASDAQ:BFRA) moved higher by 0.1% in pre-market trading after the company reported Q3 results.Quarterly Results Earnings per share were flat 0.00% year over year to ($0.00), which beat the estimate of ($0.34).Revenue of $5,508,000 declined by 1.98% from the same period last year, which missed the estimate of $5,900,000.Looking Ahead Earnings guidance hasn't been issued by the company for now.View more earnings on BFRABiofrontera hasn't issued any revenue guidance for the t...

    11/11/2020BFRA
    Biofrontera reports third quarter and first nine months 2020 results

    Leverkusen, Germany, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today published its results for the third quarter ended September 30, 2020. In addition, the Company provided an overview of the current business performance.Financial figures in EUR thousands9M 20209M 2019Q3 2020Q3 2019 Sales revenue20,829 19,059 4,713 5,155  Research and development costs(3,403)(3,215)(1,014)(894) Ge...

    11/2/2020BFRA
    Biofrontera announces conference call to be held on November 12, 2020 to discuss Q3 2020 financial results

    Leverkusen, Germany, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, will be releasing its unaudited financial results for the third quarter ended September 30, 2020 on Wednesday, November 11, 2020. Conference calls for shareholders and interested investors will be held on Thursday, November 12, 2020, at the following times:In German, November 12, 2020 at 10:00 am CET (4:00 am ET) Dial-i...